The Technical Analyst
Esperion Therapeutics Inc [ESPR]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Esperion Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.63% $1.870
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 318.68 mill |
| EPS: | -2.03 |
| P/E: | -0.920 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 170.42 mill |
| Avg Daily Volume: | 6.58 mill |
| RATING 2024-04-18 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.920 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.920 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.622 - 2.12 ( +/- 13.26%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-14 | Warren Eric | Buy | 100 000 | Common Stock |
| 2024-03-14 | Warren Eric | Buy | 150 000 | Stock Option (right to buy) |
| 2024-03-14 | Foody Joanne M. | Buy | 150 000 | Common Stock |
| 2024-03-14 | Foody Joanne M. | Buy | 200 000 | Stock Option (right to buy) |
| 2024-03-14 | Looker Benjamin | Buy | 100 000 | Common Stock |
| INSIDER POWER |
|---|
| 98.69 |
| Last 98 transactions |
| Buy: 4 476 078 | Sell: 52 346 |
Forecast:
16:00 - $1.870
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.870
Forecast 2: 16:00 - $1.870
Forecast 3: 16:00 - $1.870
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.870 (1.63% ) |
| Volume | 6.00 mill |
| Avg. Vol. | 6.58 mill |
| % of Avg. Vol | 91.16 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ESPR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.60 | N/A | Active |
|---|
ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Latest Press Releases
2024-04-07 14:45:00 - Press Release
Esperion Presents Important New Data From Clear Outcomes At Acc.24 Highlighting Value Of Nexletol® (bempedoic Acid) Tablets In Diverse Populations Including Women, Hispanics/latinx And Patients With Obesity
– patients with obesity who took nexletol were 23% less likely to experience a major adverse cardiovascular event (mace-4) compared to placebo –
2024-04-01 08:00:00 - Press Release
Esperion To Ring Nasdaq Opening Bell Today, April 1, 2024
Ann arbor, mich., april 01, 2024 (globe newswire) -- esperion (nasdaq: espr) today announced that sheldon koenig, president and ceo, will ring the nasdaq stock market (nasdaq) opening bell at 9:30 a.m. et today, april 1, 2024, to commemorate the u.s. food and drug administration's (fda) recent approval of broad new labels for esperion's products.
2024-03-26 08:00:00 - Press Release
Esperion To Participate In 23rd Annual Needham Virtual Healthcare Conference
Ann arbor, mich., march 26, 2024 (globe newswire) -- esperion (nasdaq: espr) today announced its participation in the 23rd annual needham virtual healthcare conference. sheldon koenig, president and ceo, will participate in a fireside chat on tuesday, april 9, 2024, at 12:45 pm et. the esperion management team will also host investor meetings that same day.
2024-03-25 16:00:00 - Press Release
Esperion Announces Data From Clear Outcomes Sub-groups As Poster Presentations, Moderated Session & Industry Expert Theatre To Be Presented At Acc.24
Ann arbor, mich., march 25, 2024 (globe newswire) -- esperion (nasdaq: espr) today announced the acceptance of three clear ( c holesterol l owering via b e mpedoic acid, an a cl-inhibiting r egimen) outcomes subgroup analyses as poster presentations at the 2024 american college of cardiology's annual scientific session (acc.24) in atlanta, georgia. additionally, the company will participate in a moderated session in partnership with ut southwestern medical center, host an industry expert theatre, and have a commercial and medical information booth during acc.24.
2024-03-22 18:26:00 - Press Release
U.s. Fda Approves Broad New Labels For Esperion's Nexletol® And Nexlizet® To Prevent Heart Attacks And Cardiovascular Procedures In Both Primary And Secondary Prevention Patients, Regardless Of Statin Use
Ann arbor, mich.--(business wire)--esperion (nasdaq: espr) today announced that the united states food and drug administration (fda) has approved broad new label expansions for nexletol® (bempedoic acid) tablets and nexlizet® (bempedoic acid and ezetimibe) tablets based on positive clear outcomes data that include indications for cardiovascular risk reduction and expanded ldl-c lowering in both primary and secondary prevention patients. in addition, the enhanced labels support the use of nexlet.
Latest News
2024-04-01 12:48:00 - Schwab Network
Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications
Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.
2024-03-28 12:36:50 - Zacks Investment Research
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
2024-02-29 09:56:09 - Zacks Investment Research
5 Small Drug Stocks to Buy From a Rebounding Industry
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
2024-02-28 15:13:01 - Seeking Alpha
A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Esperion Therapeutics reported strong Q4 and full-year revenue growth, with total revenue increasing 72% YoY to $32.3M in Q4 and 54% YoY to $116M for the full year. The company expects a true inflection point after receiving approval for expanded labels for its cardiovascular drugs. Esperion is preparing for a significant sales ramp starting in April, with an expanded sales force and an anticipated larger patient population.
2024-02-28 08:46:07 - Zacks Investment Research
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
2024-02-27 08:21:03 - Zacks Investment Research
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.76 per share a year ago.
2024-02-13 11:06:41 - Zacks Investment Research
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-13 08:00:00 - GlobeNewsWire
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, February 27, 2024.
2024-01-25 15:57:00 - Market Watch
This late-January stock-trading pattern has been a winner in 30 of the past 38 years
The stock market, as measured by the S&P 500 index SPX, has broken out strongly to the upside, trading at new intraday and closing highs. The breakout came on Jan. 19, over the 4,800 level.
2024-01-22 17:13:06 - Seeking Alpha
Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price. The presentation at the JP Morgan Healthcare Conference provided little new information and failed to boost the stock. The Q&A session provided some insights, including information about utilization management headwinds and the company's digital consumer campaign.